Cachexia-Pipeline Review, H1 2015

Cachexia-Pipeline Review, H1 2015

  • Products Id :- GMDHC6144IDB
  • |
  • Pages: 67
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Cachexia-Pipeline Review, H1 2015


Global Markets Direct's, 'Cachexia-Pipeline Review, H1 2015', provides an overview of the Cachexia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Cachexia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cachexia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Cachexia

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Cachexia and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Cachexia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Cachexia pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Cachexia

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Cachexia pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Cachexia Overview 8

Therapeutics Development 9

Pipeline Products for Cachexia-Overview 9

Pipeline Products for Cachexia-Comparative Analysis 10

Cachexia-Therapeutics under Development by Companies 11

Cachexia-Therapeutics under Investigation by Universities/Institutes 12

Cachexia-Pipeline Products Glance 13

Clinical Stage Products 13

Early Stage Products 14

Cachexia-Products under Development by Companies 15

Cachexia-Products under Investigation by Universities/Institutes 16

Cachexia-Companies Involved in Therapeutics Development 17

Aphios Corporation 17

AVEO Pharmaceuticals, Inc. 18

BioLineRx, Ltd. 19

Calzada Limited 20

Cytokinetics, Inc. 21

GlaxoSmithKline plc 22

MI.TO. Technology S.r.L. 23

Myos Corporation 24

Novartis AG 25

Palatin Technologies, Inc. 26

Pfizer Inc. 27

Rhythm Pharmaceuticals 28

Cachexia-Therapeutics Assessment 29

Assessment by Monotherapy Products 29

Assessment by Target 30

Assessment by Mechanism of Action 32

Assessment by Route of Administration 34

Assessment by Molecule Type 36

Drug Profiles 38

AOD-9604-Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

AV-380-Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

bimagrumab-Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

BL-5040-Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

CK-2066260-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

DLN-101-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

dronabinol-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

Drugs to Inhibit Activin Receptor for Cachexia-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

PF-06260414-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

Protein for Musculoskeletal Disorders-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

relamorelin-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

Small Molecules to Inhibit Furin for Sarcopenia and Cachexia-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

Small Molecules to Inhibit JAK3 for Sarcopenia and Cachexia-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

Small Molecules to Inversely Agonize Beta3-Adrenoreceptor for Cachexia, Metabolic Syndrome and Heart Failure-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

Small Molecules to Modulate Melanocortin-4 Receptor for Cachexia-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

Synthetic Peptide to Antagonize MC3 and MC4 Receptor for Cachexia-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

Cachexia-Recent Pipeline Updates 58

Cachexia-Dormant Projects 63

Cachexia-Discontinued Products 64

Cachexia-Product Development Milestones 65

Featured News & Press Releases 65

Mar 13, 2012: Calzada Announces Positive Results Of AOD9604 In Cartilage And Muscle Repair Models 65

Jun 04, 2002: Aphios Receives National Cancer Institute Grant For Developing Natural Cannabinoid Products for Medical Use 65

Appendix 66

Methodology 66

Coverage 66

Secondary Research 66

Primary Research 66

Expert Panel Validation 66

Contact Us 66

Disclaimer 67

List of Tables

Number of Products under Development for Cachexia, H1 2015 9

Number of Products under Development for Cachexia-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 11

Number of Products under Investigation by Universities/Institutes, H1 2015 12

Comparative Analysis by Clinical Stage Development, H1 2015 13

Comparative Analysis by Early Stage Development, H1 2015 14

Products under Development by Companies, H1 2015 15

Products under Investigation by Universities/Institutes, H1 2015 16

Cachexia-Pipeline by Aphios Corporation, H1 2015 17

Cachexia-Pipeline by AVEO Pharmaceuticals, Inc., H1 2015 18

Cachexia-Pipeline by BioLineRx, Ltd., H1 2015 19

Cachexia-Pipeline by Calzada Limited, H1 2015 20

Cachexia-Pipeline by Cytokinetics, Inc., H1 2015 21

Cachexia-Pipeline by GlaxoSmithKline plc, H1 2015 22

Cachexia-Pipeline by MI.TO. Technology S.r.L., H1 2015 23

Cachexia-Pipeline by Myos Corporation, H1 2015 24

Cachexia-Pipeline by Novartis AG, H1 2015 25

Cachexia-Pipeline by Palatin Technologies, Inc., H1 2015 26

Cachexia-Pipeline by Pfizer Inc., H1 2015 27

Cachexia-Pipeline by Rhythm Pharmaceuticals, H1 2015 28

Assessment by Monotherapy Products, H1 2015 29

Number of Products by Stage and Target, H1 2015 31

Number of Products by Stage and Mechanism of Action, H1 2015 33

Number of Products by Stage and Route of Administration, H1 2015 35

Number of Products by Stage and Molecule Type, H1 2015 37

Cachexia Therapeutics-Recent Pipeline Updates, H1 2015 58

Cachexia-Dormant Projects, H1 2015 63

Cachexia-Discontinued Products, H1 2015 64

List of Figures

Number of Products under Development for Cachexia, H1 2015 9

Number of Products under Development for Cachexia-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 11

Comparative Analysis by Clinical Stage Development, H1 2015 13

Comparative Analysis by Early Stage Products, H1 2015 14

Assessment by Monotherapy Products, H1 2015 29

Number of Products by Top 10 Targets, H1 2015 30

Number of Products by Stage and Top 10 Targets, H1 2015 30

Number of Products by Top 10 Mechanism of Actions, H1 2015 32

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 32

Number of Products by Top 10 Routes of Administration, H1 2015 34

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 34

Number of Products by Top 10 Molecule Types, H1 2015 36

Number of Products by Stage and Top 10 Molecule Types, H1 2015 36

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Aphios Corporation

AVEO Pharmaceuticals, Inc.

BioLineRx, Ltd.

Calzada Limited

Cytokinetics, Inc.

GlaxoSmithKline plc

MI.TO. Technology S.r.L.

Myos Corporation

Novartis AG

Palatin Technologies, Inc.

Pfizer Inc.

Rhythm Pharmaceuticals

Cachexia Therapeutic Products under Development, Key Players in Cachexia Therapeutics, Cachexia Pipeline Overview, Cachexia Pipeline, Cachexia Pipeline Assessment

select a license

Single User License
USD 2000 INR 136180
Site License
USD 4000 INR 272360
Corporate User License
USD 6000 INR 408540



Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]